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Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed pri-
marily to refine and make headway in the prognostic stratification of advanced ACC.
Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between
2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of
potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 ‘before
surgery’; model 2 ‘post-surgery’.
Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed.
After a median follow-up of 55.2 months, the median OS was 24 months. A modified ENSAT (mENSAT) classification
was validated: stage III (invasion of surrounding tissues/organs or the vena renalis/cava) and stage IVa, IVb, IVc (2, 3 or >3
metastatic organs, including N, respectively). Two- or 5-year OS was 73%, 46%, 26% and 15% or 50%, 15%, 14% and
2% for stages III, IVa, IVb and IVc, respectively. In the multivariate analysis, mENSAT stages (stages IVa, IVb, or IVc, re-
spectively) were significantly correlated with OS (P < 0.0001), as well as additional parameters: age ≥50 years
(P < 0.0001), tumor- or hormone-related symptoms (P = 0.01 and 0.03, respectively) in model 1 but also the R status
(P = 0.001) and Grade (Weiss >6 and/or Ki67 ≥20%, P = 0.06) in model 2.
Conclusion: The mENSAT classification and GRAS parameters (Grade, R status, Age and Symptoms) were found to
best stratify the prognosis of patients with advanced ACC.
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introduction
Adrenocortical carcinoma (ACC) is a rare malignancy with an
estimated yearly incidence of 0.7–2.0 cases per million
inhabitants [1, 2] and a very aggressive behavior [2–5].
Historically, the prognosis of ACC was shown to be mainly
driven by the presence of metastases and tumor resecability [6].
More recently, the European Network for the Study of Adrenal
Tumors (ENSAT) classification of TNM stages and the resection
status has refined prognostication [4, 5, 7].
Advanced ACC, defined as tumor stage III, in the case of loco-
regional spread, or stage IV, in the case of distant metastases, re-
present 18%–26% and 21%–46% of ACC at diagnosis, respectively
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[2–5]. Treatment options for such patients are limited [8, 9], and
no predictors of response have been validated. The best way to
stratify the prognosis of advanced ACC continues to fuel debate.
Indeed, several studies suggest that patients with stage III disease
and positive lymph nodes (N1) or vena cava invasion could have a
similar prognosis to that of those with stage IV disease [7, 10, 11].
The number of tumor-involved organs in patients with stage IV
ACC has been reported to be useful for refining the prognosis of
these patients as well [12]. Furthermore, several studies also claim
that age, hormone secretion, the Weiss score and/or proliferative
index and the resection (R) status may also exert an impact on the
prognosis of these patients [13–17]. Better prognostic stratification
is therefore needed in advanced ACC [8, 9].
The objective of this retrospective study was to refine the
prognostic classification of patients with advanced stage III
and stage IVACC at diagnosis. To achieve this goal, the ENSAT
registry, comprising a large number of ACC patients treated in
expert centers in four European countries, was utilized.
patients andmethods
patient and data collection
From 1 January 2000 to 31 December 2009, 463 patients with stage III or IV
ACC followed up in 16 expert referral centers in four European countries
(Germany, France, Italy and The Netherlands) were consecutively registered
in the ENSATACC Registry. Inclusion criteria were: a confirmed histological
diagnosis of ACC, stage III–IV disease at imaging and/or surgery carried out
within 3 months of the diagnosis, age >18 years and available follow-up data.
Data collected included: age, sex, modality of tumor diagnosis [defined as :
incidental, symptom-related either to the tumor mass (i.e. abdominal pain) or
hormone secretions (glucocorticoids, mineralocorticoids, androgens hyperse-
cretion) or other/unknown], ENSAT or UICC TNM classifications (tumor
size, invasion of adjacent tissue/organs or vena cava/renalis vein, lymph node
or distant metastases), involved organs, tumor grade based on the pathological
analysis of the primary tumor [defined as the Weiss score (≤6/>6) or Ki67
percentage (<20%/≥20%)], the R status at first surgery (complete resection:R0;
microscopic residual disease:R1; macroscopic residual disease:R2, resection
not-known: Rx).
The ENSAT registry was approved by the local ethics committees of all par-
ticipating centers and all patients included had given their written informed
consent.
evaluation of different stage III–IV definitions and
tumor grading systems
In order to validate the best way to stratify the TNM classification of
advanced ACC patients, four different TNM classification systems were com-
pared before the final prognostic analysis: the UICC, ENSAT and two pro-
posed modified ENSAT classifications (mENSAT).
The two mENSAT classifications were constructed as described in supple-
mentary Figure S1A and B, available at Annals of Oncology online by analyz-
ing independently the prognostic influence of N status and venous invasion.
In addition, stage IV was categorized into subgroups according to the
number of tumor-involved organs (IVa: 2, IVb: 3, IVc: >3 organs).
In order to classify the tumor grade, three different classifications were
analyzed as described in supplementary Figure S2A–C, available at Annals of
Oncology online, by analyzing the prognostic influence of the Weiss score,
Ki67 or a combination of both parameters.
Patients whose Weiss score and Ki67 were both missing, as well as
patients who have no adrenalectomy, were excluded from the analysis.
Parameter selection and combinations were carried out graphically, using
the Kaplan–Meier and the Hall–Wellner confidence intervals of each curve.
The parameters considered to best reflect the tumor burden and the tumor
grade were those allowing the greatest discrimination of patients in terms of
overall survival (OS), graphically.
statistics
Descriptive analyses were carried out using means and standard deviations
for quantitative variables, and comparisons were carried out using the
Student test (or non-parametric Wilcoxon test if non-normally distributed).
Qualitative variables were expressed as percentages and comparisons were
carried out using the χ2 test.
The primary end point was OS, defined as the interval between the date of
the diagnosis of stage III or IV ACC and death due to any cause. Surviving
patients were censored at the date of the last follow-up. Follow-up data were
last updated in November 2012. The median follow-up was estimated by the
reverse Kaplan–Meier method (Schemper’s method).
Survival rates and 95% confidence intervals were estimated by the
Kaplan–Meier method. The log-rank test was used to compare survival
curves. The parameters significantly associated with OS in the univariate
analysis (P < 0.05) were further tested in the multivariate analysis. Hazard
ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using
Cox’s proportional hazards regression model in the multivariate analysis,
with the lowest risk group as the reference group. All tests were two sided.
Variables, as well as cut-off thresholds, are presented in supplementary
Table S1, available at Annals of Oncology online: they were analyzed for their
potential prognostic value in the univariate analysis.
Two multivariate analyses were carried out: model 1 (before-surgery)
analyzed all prognostic parameters available at the time of ACC diagnosis.
Model 2 (post-surgery) analyzed all prognostic parameters including the
pathological grade and R status in patients who underwent adrenalectomy.
The statistical analysis was conducted using SAS software version 9.2.
results
population characteristics and follow-up data
Four hundred and sixty-three cases were reviewed: 15 were
excluded because <18 years old and 4 because lost at follow-up.
Thus, 444 patients constituted the study population: 210 (47%)
were ENSAT stage III and 234 (53%) stage IV. The main popu-
lation characteristics are summarized in Table 1.
Supplementary Table S2, available at Annals of Oncology
online describes the different treatments received by the patients
during the first year of therapy. Patients with stage III under-
went significantly more frequently surgery than those with stage
IV: no surgery was carried out in 6 ENSAT stage III patients
and in 54 ENSAT stage IV patients.
The median follow-up of patients was 55.2 (range 0–139)
months. The median OS was 24 (21.6–27.7) months. The 2-
and 5-year survival rates were 50% (CI 45%–55%) and 27%
(CI 23%–31%), respectively.
selection of the best TNM and pathology
classifications in advanced ACC patients
N-positive status but not venous invasion outcome was found to
overlap with stage IV outcome (supplementary Figure S1A and
B, available at Annals of Oncology online). Therefore, the first
mENSAT classification was considered to better stratify the
prognosis of patients with stage III–IVACC. It defined stage III
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as T3–4N0M0 and stage IVa, IVb, IVc according to the number
of tumor-involved organs (including the primary tumor and the
‘N’ as ‘organ’): 2, 3 or >3, respectively (supplementary Table S3,
available at Annals of Oncology online). ENSAT and mENSAT
classifications were found to be more informative than their
UICC counterpart (Figure 1A–C).
Regarding pathological grading, prognostic information but
also the number of available data were taken into account.
Both Ki67 and the Weiss score significantly discriminated OS
outcome in the univariate analysis. However, Ki67 had not
been documented in a significant number of patients. The
Weiss score and/or Ki67 were available in 340 patients and the
combination of the two pathological parameters allowed us to
significantly discriminate two subgroups of patients, in terms
of OS (supplementary Figure S2A–C, available at Annals of
Oncology online) and to apply this pathological classification.
prognostic factors for OS
univariate analysis. In the univariate analysis, the following
parameters were significantly inversely associated with OS: age
≥50 years, tumor or hormone-related symptoms at diagnosis,
ENSAT, mENSAT classification, the R status, Weiss score >6
and Ki67 ≥20% (supplementary Table S1, available at Annals of
Oncology online).
In the mENSAT classification, stage III, IVa, IVb and IVc
were significantly associated with OS. In particular, the median
OS in stage III, IVa, IVb and IVc was 60.8 (CI 39.8–81.5), 21.2
(CI 15.7–25.9), 12.1 (CI 9.4–14.9) and 13.6 (CI 8.6–15.8)
months, respectively. Specifically, 2-year OS was 73% (CI 66%–
79%), 46% (CI 37%–54%), 26% (CI 16%–37%) and 15% (CI
7%–25%) for stages III, IVa, IVb and IVc and 5-year OS was
50% (CI 44%–60%), 15% (CI 8%–22%), 14% (CI 6%–24%) and
2% (CI 0.01%–9%) for stages III, IVa, IVb and IVc, respectively.
multivariate analysis: models 1 and 2. In the multivariate
analysis (model 1), the following parameters were significantly
and independently associated with an increased risk of death: age
≥50 years (P < 0.0001), tumor- or hormone-related symptoms
(P = 0.01, 0.03, respectively), the mENSAT stage (all P < 0.0001)
(Table 2). When Nx patients were excluded or considered as a
separate subgroup, the results remained unchanged.
Table 1. Clinical and pathological characteristics of 444 patients
with advanced adrenocortical carcinoma
Parameters n of patients (%) n of assessable
patients
Patients 444 444
Age(years)
<50 200 (45%) 444
≥50 244 (55%)
Gender
Male 173 (39%) 444
Female 271 (61%)
Modality of diagnosis
Tumor-related symptoms 163 (37%) 444
Hormone-related symptoms 144 (32%)
Incidentally 65 (15%)
Other/unknown 72 (16%)
ENSAT stage
III 210 (48%) 444
IV 234 (52%)
Modified ENSAT stage (mENSAT)
III 177 (40%) 444
IVa 139 (31%)
IVb 65 (15%)
IVc 63 (14%)
Tumor (T)
T1 11 (2%) 444
T2 97 (22%)
T3 140 (32%)
T4 196 (44%)
Regional lymph nodes (N1)
Y 98 (22%) 444
N 202 (45%)
Unknown 144 (32%)
Organ metastases (M1)
Lung
Y 152 (34%) 444
N 292 (65%)
Liver
Y 125 (28%) 444
N 319 (72%)
Bone
Y 32 (7%) 444
N 412 (93%)
Adrenalectomy
Y 384 (86%) 444
N 60 (14%)
R status in resected patients
R0a 150 (39%) 384
R1 34 (9%)
R2 91 (24%)
Rx 109 (28%)
Weiss score
≤ 6 174 (53%) 327
>6 153 (47%)
Ki 67 (%)
<20 103 (46%) 226
≥ 20 123 (54%)
Continued
Table 1. Continued
Parameters n of patients (%) n of assessable
patients
Death
Y 301 (68%) 444
N 143 (32%)
Alive
With disease or recurrence 76 (53%) 143
Without disease 63 (44%)
Unknown 4 (3%)
aPrimary including metastases in 43 patients.
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Figure 1. Overall survival according to UICC (A), ENSAT (B) and m-ENSAT (C) TNM classifications in 444 advanced adrenocortical carcinoma patients.
Table 2. Multivariate analyses (models 1 and 2)
Model 1 (n = 444 patients) Model 2 (n = 340 patients)
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age
<50 years 1 1 1 1
≥50 years 1.6 1.3–2.1 <0.0001 1.3 1.01–1.8 0.04
Modality of diagnosis
Incidentally 1 1 1 1
Tumor mass 1.7 1.1–2.5 0.01 1.8 1.1–2.8 0.01
Hormone hypersecretion 1.6 1.05–2.4 0.03 1.5 0.97–2.5 0.06
Other or unknown 1.2 0.8–1.9 0.40 1.05 0.6–1.8 0.83
Modified ENSAT stage
III 1 1 1 1
IVa 2.6 2.0–3.5 <0.0001 2.1 1.5–2.9 <0.0001
IVb 3.6 2.5–5.1 <0.0001 2.4 1.5–3.7 <0.0001
IVc 5.1 3.6–7.3 <0.0001 4.3 2.7–6.5 <0.0001
Tumor grade NA
Weiss ≤6 and Ki <20 1 1
Weiss >6 and or Ki ≥20 1.3 0.99–1.7 0.06
R status NA
R0 1 1
R 1, 2, X 1.6 1.2–2.2 0.001
Model 1: prognostic model with clinical variables, without pathology and the R status; model 2: prognostic model with clinical variables, with pathology
and the R status.
NA, not applicable.
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With model 2, the following parameters were significantly
associated with an increased risk of death: age ≥50 years
(P < 0.04), tumor-related symptoms (P = 0.01), the mENSAT
stages (all P < 0.0001) and the R status (P = 0.001). The HR of
the tumor grade (Weiss >6 and/or Ki67 ≥20%) reached 1.3
and the hormone-related symptoms at diagnosis was 1.5, with a
P-value that tended to be significant for both variables
(P = 0.06). When Rx patients were excluded or considered as a
separate subgroup, the results remained unchanged.
In the following section, the acronym ‘GRAS’, used to desig-
nate Grading (G), the R status (R), Age (A) and Symptoms (S),
defined as tumor- or hormone-related symptoms at diagnosis,
corresponds to these parameters.
combining prognostic parameters. We then attempted to refine
the prognostic classification of ACC by combining the mENSAT
stage with the GRAS parameters. Age ≥50 years and/or presence
of symptoms were first combined with mENSAT stages III and
IVa in model 1 (Figure 2A and B). Unfavorable grading or the R
status was subsequently combined with the same mENSAT stages
in model 2 (Figure 3A and B).
Figures 2 and 3 show that these GRAS parameters signifi-
cantly affect the prognosis of mENSAT stage III or IVa. Five-
year OS of mENSAT stage III was 50% but ranged from 68%,
for age <50 years and an incidental tumor (Figure 2A) in model
1 to 22% when tumor grading and the R status were unfavorable
in model 2 (Figure 3A).
Five-year OS of mENSAT stage IVa was 15% but ranged from
0% to 55% when age and functional symptoms were unfavorable
or favorable in model 1 (Figure 2B), respectively, and ranged
from 16% to 46% when tumor grading and the R status were un-
favorable or favorable in model 2 (Figure 3B).
discussion
This collaborative study of the ENSAT network allowed us to
refine the prognostic classification in a large and typical group
of patients with advanced ACC defined as stage III or synchron-
ous stage IV disease [3, 5, 12]. We propose a new mENSAT
TNM classification and confirm the prognostic value of four
additional prognostic parameters named ‘GRAS’ parameters.
The tumor stage, best defined by the mENSAT classification,
was confirmed as the keystone of the prognostic stratification. We
investigated the prognostic role of the N status together with
venous invasion and we found that the N1 status plays a deleteri-
ous prognostic role comparable to stage IV ACC, as previously
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reported [7, 10]. In addition, we confirmed the prognostic value
of the number of tumor-involved organs, including the primary
and lymph node involvement [12]. On the basis of these results,
we created a new prognostic TNM classification restricted to
patients with advanced ACC, the mENSAT stage III–IV classifi-
cation, which allowed us to unambiguously discriminate the
prognostic outcomes of four categories of patients namely, stage
III, IVa, IVb and IVc with 5-year OS rates of 50%, 15%, 14% and
2%, respectively. In this new classification, the N1 status shifts
tumors from ENSAT stage III to the mENSAT stage IV category
(i.e. IVa, if the N1 is isolated). In contrast, the prognosis of ACC
with venous invasion was found to be comparable to that of other
subgroups of stage III N0 disease. However, a limitation of our
study is the fact that vena cava or vena renalis invasion was not
accurately documented in all cases [5]. Furthermore, it should be
borne in mind that the N classification used in our study refers to
both imaging and pathological classifications and future refine-
ments are expected. These results may suggest that surgical exci-
sion of the ACC primary tumor including venous invasion is
better handled by ACC surgeons than lymph node dissection
whose putative role has only been underlined recently [11, 18].
In addition to the mENSAT classification, we validated for
the first time, after optimization and adjustment for the tumor
burden in advanced ACC, four additional prognostic para-
meters, designated GRAS, that were found to affect the progno-
sis of each mENSAT stage.
Indeed, 5-year OS of stage III patients ranged between 60%
and 70% in patients <50 years-old with an incidentally discovered
ACC or with an R0 status and favorable tumor grading but
dropped to 22% when the tumor grade and the R status were
both found to be unfavorable. Five-year OS for patients with stage
IVa disease was 15% but ranged from 0 to 55% in patients with
favorable or unfavorable GRAS parameters, again suggesting an
overlap between patients with stage III and IVa disease. The valid-
ation of the precise prognostic roles of each parameter and the
combination of GRAS parameters require additional studies in
larger and independent group of patients to better understand the
magnitude of their influence for each stage. Meanwhile, standard-
ization, including quantification when feasible, of the analysis of
each prognostic parameter is required.
Age was expressed as a binomial parameter according to the
median in this study which may be optimized. Also future
studies should investigate more precisely how far the magnitude
and subtypes of secretions affect the prognosis [13, 15]. The
prognostic influence of the Weiss score in comparison to the
Ki67 index, but also standardization of their analyses in all pa-
tients and comparisons of the informative value of the primary
and metastasis require further studies.
The R0 status of the primary was identified as a major prog-
nostic parameter in our study, suggesting that the benefit of the
R0 status applies not only to stage III but also to stage IV.
However, the R status can be considered a surrogate for the
tumor burden but also reflects the surgeon’s expertise which is
difficult to analyze objectively. In addition, the best time to
perform R0 resection remains to be more precisely defined.
The strengths of this study include the large number of patients
based on national expert European networks together with pro-
longed follow-up allowing robust conclusions in this rare cancer.
The limitations of this study include its retrospective nature
explaining the lack of consistency for pathological, R and N status
reports. In addition, as for all prognostic studies, the impact of
therapeutic intervention was not analyzed which may affect the
results. Standardization and further validations of the mENSAT-
GRAS parameters are however warranted in a prospective cohort
of patients as well as the analysis of the added value of the recent-
ly published molecular classification of ACC patients [19].
conclusion
The mENSAT classification was found to best stratify the prognosis
of advanced ACC patients. After adjustment to the mENSAT classi-
fication, four additional prognostic ‘GRAS’ parameters were found.
Prospective validation of this new prognostic system is expected.
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Bevacizumab/high-dose chemotherapy
with autologous stem-cell transplant for poor-risk
relapsed or refractory germ-cell tumors
Y. Nieto1*, S. -M. Tu2, R. Bassett3, R. B. Jones1, A. M. Gulbis4, N. Tannir2, A. Kingham1,
C. Ledesma1, K. Margolin5, L. Holmberg5, R. Champlin1 & L. Pagliaro2
Departments of 1Stem Cell Transplantation and Cellular Therapy; 2Genitourinary Medical Oncology; 3Biostatistics; 4Pharmacy, University of Texas
MD Anderson Cancer Center, Houston; 5Department of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, USA
Received 22 May 2015; revised 1 July 2015; accepted 10 July 2015
Background: High-dose chemotherapy (HDC) using sequential cycles of carboplatin/etoposide is curative for relapsed
germ-cell tumors (GCT). However, outcomes of high-risk patients in advanced relapse remain poor. We previously devel-
oped a new HDC regimen combining infusional gemcitabine with docetaxel/melphalan/carboplatin (GemDMC), with
preliminary high activity in refractory GCT. Given the high vascular endothelial growth factor expression in metastatic GCT
and the synergy between bevacizumab and chemotherapy, we studied concurrent bevacizumab and sequential HDC
using GemDMC and ifosfamide/carboplatin/etoposide (ICE) in patients with poor-risk relapsed or refractory disease.
Patients and methods: Eligibility criteria included intermediate/high-risk relapse (Beyer Model), serum creatinine ≤1.8
mg/dl and adequate pulmonary/cardiac/hepatic function. Patients received sequential HDC cycles with bevacizumab
preceding GemDMC (cycle 1) and ICE (cycle 2). The trial was powered to distinguish a target 50% 2-year relapse-free
survival (RFS) from an expected 25% 2-year RFS in this population.
Results: We enrolled 43 male patients, median age 30 (20–49) years, with absolute refractory (N = 20), refractory
(N = 17) or cisplatin-sensitive (N = 6) disease, after a median 3 (1–5) prior relapses. Disease status right before HDC was
unresponsive (N = 24, progressive disease 22, stable disease 2), partial response with positive markers (PRm+) (N = 8),
PRm− (N = 7) or complete response (N = 4). Main toxicities were mucositis and renal. Four patients (three with baseline
marginal renal function) died from HDC-related complications. Tumor markers normalized in 85% patients. Resection of
residual lesions (N = 13) showed necrosis (N = 4), mature teratoma (N = 2), necrosis/teratoma (N = 3) and viable tumor
(N = 4). At median follow-up of 46 (9–84) months, the RFS and overall survival rates are 55.8% and 58.1%, respectively.
Conclusions: Sequential bevacizumab/GemDMC–bevacizumab/ICE shows encouraging outcomes in heavily pre-
treated and refractory GCT, exceeding the results expected in this difficult to treat population.
ClinicalTrials.gov: NCT00936936.
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